Table 3.

The association between relative expression level of 4 lncRNAs and clinicopathologic characteristics

		EMP1-008			ATF3-008			RCOR3-013			TMEM63A-005
Variable	N	Mean	SD	95% CI	Mean	SD	95% CI	Mean	SD	95% CI	Mean	SD	95% CI
				P. value			P. value			P. value			P. value
Age (y)
< 60	19	2.63	4.51	(-3.14, 3.60)	-0.09	3.54	(-1.43, 3.58)	1.34	3.57	(-2.33, 2.58)	0.47	1.99	(-1.653, 1.777)
≥ 60	13	2.4	4.68	0.89	-1.17	3.19	0.388	1.22	2.98	0.917	0.41	2.77	0.941
Gender
F	15	1.82	4.85	(-4.62, 1.94)	-0.02	3.72	(-1.51, 3.43)	0.71	3.4	(-3.47, 1.30)	0.35	1.77	(-1.869, 1.504)
M	17	3.16	4.23	0.412	-0.98	3.12	0.431	1.8	3.21	0.359	0.53	2.73	0.826
Adbominal_pain
0	18	2.61	4.33	(-3.16, 3.51)	-0.82	3.03	(-3.17, 1.83)	0.83	2.99	(-3.46, 1.34)	0	2.5	(-2.672, 0.638)
1	14	2.44	4.89	0.917	-0.15	3.89	0.586	1.89	3.66	0.374	1.02	1.93	0.219
Cirrhosis
0	26	2.71	4.69	(-3.28, 5.17)	-0.87	3.55	(-4.94, 1.29)	1.02	3.5	(-4.49, 1.60)	0.81	1.91	(-0.079, 3.984)
1	6	1.77	3.9	0.652	0.95	2.23	0.241	2.47	1.95	0.34	-1.14	3.27	0.059
Hepatitis
0	18	2.52	4.48	(-3.37, 3.30)	-0.94	3.36	(-3.42, 1.55)	1	3.11	(-3.09, 1.75)	0.49	2.14	(-1.597, 1.798)
1	14	2.55	4.72	0.983	0	3.49	0.448	1.67	3.59	0.575	0.39	2.56	0.905
CA199 (U/ml)
0 (< 40)	14	2.75	4.31	(-2.96, 3.71)	0.16	3.07	(-1.25, 3.69)	1.36	3.39	(-2.32, 2.55)	-0.23	2.31	(-2.848, 0.426)
1 (≥ 40)	18	2.37	4.78	0.819	-1.06	3.62	0.321	1.24	3.31	0.923	0.98	2.2	0.141
AFP (IU/ml)
0 (< 20)	26	2.74	4.6	(-3.13, 5.31)	-0.32	3.66	(-2.06, 4.27)	1.58	3.39	(-1.53, 4.55)	0.78	1.69	(-0.31, 3.80)
1 (≥ 20)	6	1.65	4.37	0.603	-1.42	1.78	0.482	0.07	2.73	0.319	-0.97	3.93	0.094
CEA (ng/ml)
0 (< 5)	27	2.11	4.67	(-7.16, 1.73)	-0.75	3.25	(-4.79, 1.99)	1.18	3.4	(-4.03, 2.60)	0.32	2.39	(-3.11, 1.49)
1 (≥ 5)	5	4.82	2.86	0.222	0.65	4.33	0.407	1.89	2.9	0.664	1.13	1.71	0.48
CA125 (U/ml)
0 (< 35)	22	2.9	4.04	(-2.38, 4.70)	-0.73	2.98	(-3.31, 2.04)	1.19	2.97	(-2.92, 2.29)	0.36	2.42	(-2.086, 1.543)
1 (≥ 35)	10	1.74	5.56	0.509	-0.09	4.32	0.633	1.51	4.08	0.807	0.64	2.1	0.762
CA153 (U/ml)
0 (< 25)	26	2.59	4.2	(-3.92, 4.55)	-0.2	3.17	(-1.37, 4.87)	1.01	2.91	(-4.54, 1.54)	0.68	1.88	(-0.86, 3.35)
1 (≥ 25)	6	2.28	6.13	0.88	-1.95	4.27	0.261	2.51	4.77	0.322	-0.56	3.67	0.236
CA724 (U/ml)
0 (< 10)	27	2.43	4.5	(-5.22, 3.88)	-0.73	3.34	(-4.66, 2.14)	1.12	3.38	(-4.38, 2.22)	0.71	1.89	(-0.59, 3.88)
1 (≥ 10)	5	3.1	5.03	0.765	0.54	3.85	0.454	2.2	2.92	0.509	-0.94	3.84	0.144
CA242 (U/ml)
0 (< 20)	19	3	3.98	(-2.18, 4.50)	0.07	3.3	(-1.00, 3.95)	1.5	3.12	(-1.94, 2.96)	0.4	2.27	(-1.840, 1.589)
1 (≥ 20)	13	1.85	5.28	0.485	-1.41	3.47	0.233	0.99	3.63	0.673	0.52	2.42	0.882
Tumor_size (cm)
0 (< 5)	16	3.32	4.37	(-1.69, 4.83)	0.1	2.99	(-1.19, 3.70)	1.09	2.69	(-2.81, 2.01)	0.9	1.62	(-0.743, 2.557)
1 (> 5)	16	1.75	4.65	0.332	-1.16	3.74	0.304	1.49	3.88	0.739	0	2.8	0.271
Tumor_metastasis
0	21	3.95	4.15	(0.99, 7.24)	0.79	3.13	(1.63, 6.03)	2.19	3.14	(0.28, 4.97)	0.43	2.39	(-1.823, 1.724)
1	11	-0.17	4.05	0.012	-3.04	2.35	0.001	-0.43	2.98	0.03	0.48	2.22	0.955
Tumor_number
Single	21	2.48	4.44	(-3.65, 3.32)	-0.6	3.24	(-2.83, 2.41)	1.51	3.38	(-1.90, 3.16)	0.24	1.99	(-2.357, 1.161)
Mulitple	11	2.64	4.86	0.925	-0.39	3.84	0.869	0.88	3.23	0.613	0.84	2.85	0.493
HBsAg
0	24	2.59	4.28	(-3.62, 4.02)	-0.78	3.28	(-3.84, 1.86)	1.26	3.25	(-2.92, 2.66)	0.51	2.39	(-1.709, 2.178)
1	8	2.38	5.47	0.914	0.21	3.84	0.484	1.39	3.63	0.926	0.27	2.11	0.807
CK18
0	18	1.67	4.18	(-5.23, 1.27)	-1.66	3.12	(-4.90, -0.26)	0.97	3.17	(-3.16, 1.68)	0.12	2.73	(-2.422, 0.928)
1	14	3.65	4.82	0.223	0.92	3.27	0.03	1.71	3.51	0.535	0.87	1.57	0.37
CK19
0	25	2.29	4.62	(-5.11, 2.86)	-0.91	3.28	(-4.68, 1.20)	1.2	3.28	(-3.34, 2.49)	0.18	2.49	(-3.204, 0.768)
1	7	3.41	4.31	0.568	0.83	3.7	0.237	1.63	3.56	0.767	1.4	1.06	0.22
CD10
0	24	2.4	4.39	(-4.33, 3.30)	-0.37	3.49	(-2.24, 3.49)	1.53	3.13	(-1.82, 3.71)	0.79	1.85	(-0.495, 3.257)
1	8	2.92	5.15	0.784	-1	3.26	0.66	0.59	3.86	0.492	-0.59	3.23	0.143
OPN
0	17	1.91	4.89	(-4.62, 1.94)	-0.64	3.38	(-2.72, 2.27)	1.21	3.13	(-2.59, 2.24)	0.19	2.15	(-2.236, 1.114)
1	15	3.24	4.08	0.412	-0.41	3.52	0.854	1.39	3.57	0.883	0.75	2.49	0.499